MUMBAI, India, Sept. 22 -- Intellectual Property India has published a patent application (202648109367 A) filed by Sinai Health System on September 11, 2026, for Allograft Tolerance Without The Need For Systemic Immune Suppression.
Inventors include Nagy, Andras; Harding, Jeffrey; and Nagy, Kristina.
The application for the patent was published on September 18, 2026, under issue no. 38/2026.
Abstract: A cell genetically modified to comprise at least one mechanism for providing a local immunosuppression at a transplant site when transplanted in an allogeneic host, and methods for making and using the same are provided. The cell comprises a set of transgenes, each transgene encoding a gene product that is cytoplasmic, membrane bound, or local acting, and whose function is one or more of: to mitigate antigen presenting cell activation and function; to mitigate graft attacking leukocyte activity or cytolytic function; to mitigate macrophage cytolytic function and phagocytosis of allograft cells; to induce apoptosis in graft attacking leukocytes; to mitigate local inflammatory proteins; and to protect against leukocyte-mediated apoptosis. The transgenes comprise two or more of the following genes: PD-L 1, HLAG or H2- M3, Cd47,Cd200, FASLG or Fasl, Ccl21 or Ccl21b, Mfge8, and Serpin B9 or Spi6.
Disclaimer: Curated by HT Syndication.
